Avaliação do risco de internação hospitalar de idosos da comunidade no município de Porto Alegre / Assessment o f the risk of hospitalization among the elderly community in Porto Alegre

O crescimento da população idosa vem motivando mudanças nos modelos assistenciais buscando incorporar a identificação, avaliação e tratamento de idosos com perfis mórbidos e funcionais variados. O objetivo do artigo foi identificar o Risco de Internação Hospitalar (RIH) em idosos do município de Porto Alegre. O estudo foi do tipo transversal quantitativo descritivo, por meio da aplicação de questionário de triagem de RIH previamente validado. A amostra foi composta por 80 idosos com idade de 65 anos ou mais, residentes em dois setores censitários na área adstrita de uma Unidade Básica de Saúde. Calculou-se o RIH através de analise de regressão logística sendo classificado em estratos baixo, médio, médio-alto e alto. Identificou-se maior prevalência dos estratos de RIH baixo 47,5% (n = 38) e médio 20% (n = 16). Os resultados desta pesquisa indicam a necessidade de integrar a prevenção de agravo e promoção de saúde no planejamento em saúde a fim de atingir a assistência adequada ao idoso.

The growth of the elderly population has motivated changes in health care models seeking to incorporate the identification, assessment and treatment of elderly patients with morbid and functional profiles varied. The objective was to identify the Risk of Hospitalization (RIH) elderly in the city of Porto Alegre. The study was a cross-sectional descriptive quantitative, through a questionnaire screening RIH previously validated. The sample consisted of 80 elderly aged 65 years or older residing in two census tracts in the area enrolled in a Basic Health Unit. RIH was calculated by logistic regression analysis in strata being rated low, medium, medium-high and high. We identified a higher prevalence of low strata RIH 47.5% (n = 38) and average 20% (n = 16). The results of this research indicate a need to integrate injury prevention and health promotion in health planning in order to achieve adequate assistance to the elderly.

Randomized double-blind clinical trial of a new human epoetin versus a commercially available formula for anemia control in patients on hemodialysis

OBJECTIVES: Anemia is a common complication among chronic kidney disease patients on hemodialysis, occurring mostly due to erythropoietin deficiency. This randomized noninferiority trial sought to compare the efficacy and safety of a new epoetin formulation developed by Bio-Manguinhos, a biologics manufacturer affiliated with the Brazilian government, with those of a commercially available product currently used in Brazil (a biosimilar epoetin formulation). METHODS: The sample size needed to enable demonstration of noninferiority with a statistical power of 85% for a between-group difference in hemoglobin levels of no more than 1.5 g/dL was calculated. In total, 74 patients were randomly assigned to receive the epoetin formulation from Bio-Manguinhos (n = 36) or the biosimilar epoetin formulation (n = 38) in a double-blind fashion. The inclusion criteria were current epoetin therapy and stable hemoglobin levels for at least 3 months prior to the study. The primary and secondary outcomes were mean monthly hemoglobin levels and safety, respectively. The dose was calculated according to international criteria and adjusted monthly in both groups according to hemoglobin levels and at the assistant physicians' discretion. Iron storage was estimated at baseline and once monthly. Clinicaltrials.gov: NCT01184495. RESULTS: The study was conducted for 6 months after randomization. The mean baseline hemoglobin levels were 10.9±1.2 and 10.96±1.2 g/dL (p = 0.89) in the Bio-Manguinhos epoetin and biosimilar epoetin groups, respectively. During the study period, there was no significant change in hemoglobin levels in either group (p = 0.055, ANOVA). The epoetin from Bio-Manguinhos was slightly superior in the last 3 months of follow-up. The adverse event profiles of the two formulations were also similar. CONCLUSIONS: The epoetin formulations tested in this study are equivalent in efficacy ...

Diálise peritoneal (DP) como tratamento da insuficiência cardíaca congestiva (ICC) em pacientes com doença renal crônica estágio IV / Peritoneal dialysis for treating congestive heart failure in patients with stage IV chronic kidney disease

A insuficiência Cardíaca Congestiva (ICC) é uma patologia com incidência crescente e que representa uma codição de grande impacto na saúde pública, com alta morbidade e mortalidade. O excesso de volume é uma complicação prevalente, presente em 80% dos pacientes atendidos com o diagnóstico de ICC. Estaratégias farmacológicas e não farmacológicas no manejo terapêutico da ICC visam ao melhor manejo do volume e à redução no uso de diuréticos. A ultrafiltração extracorpórea tem evidenciado melhor controle de peso, redução nos dias de hospitalização e re-hospitalização dos pacientes com ICC. Neste artigo, relatamos dois casos atendidos no Hospital de Clínicas de Porto Alegre, relativos a pacientes com diagnóstico de ICC tratados com diálise peritoneal.

Congestive heart failure (CHF) is a disease with increasing incidence and codição representing a great impact on public health with high morbidity and mortality. Excess volume is a prevalent complication in 80% of patients treated with the diagnosis of CHF. Estaratégias pharmacological and nonpharmacological treatment of CHF in the aim to better manage the volume and reduce the use of diuretics. Extracorporeal ultrafiltration has shown better weight control, reduction in days of hospitalization and rehospitalization in patients with CHF. We report two cases treated at the Hospital de Clinicas de Porto Alegre, relative to patients with CHF treated with peritoneal dialysis.

Anemia e uso de eritropoetina nos pacientes em hemodiálise no Hospital de Clínicas de Porto Alegre / Anemia and use of erythropoietin in hemodialysis patients at Hospital de Clínicas de Porto Alegre

Anemia é freqüente em pacientes com insuficiência renal crônica e deve-se,principalmente, à diminuição da síntese endógena de eritropoetina. Desde a década de1980, o uso da eritropoetina recombinante tornou-se o tratamento de escolha da anemianesses pacientes.Realizamos um estudo com os pacientes em hemodiálise na Unidade de Hemodiálisedo Hospital de Clínicas de Porto Alegre, tendo encontrado uma porcentagem de 82,6%desses indivíduos em uso de eritropoetina recombinante (epoetina). A dose semanal médiade epoetina observada foi de 10.260 UI. A hemoglobina média dos pacientes foi de 10,3 g/dL; quando avaliamos a variação entre os valores médios de Hb dos pacientes em usodessa medicação, entre os meses de setembro de 2005 e fevereiro de 2006, não houvesignificância na mesma.

Anemia is a very common finding in the course of chronic renal failure; the main cause ofthis pathology is reduced production of endogenous erythropoietin. Since the 1980’s, the userecombinant human erythropoietin has become the treatment of choice for anemia in this groupof patients.We conducted a study with hemodialysis patients in the Hemodialysis Unit at Hospital deClínicas de Porto Alegre, a university hospital in southern Brazil. We found that 82.6% of thepatients were using recombinant erythropoietin (epoetin). The average weekly epoetin dose was10,260 IU. Mean hemoglobin value was 10.3 g/dL and there was no significant difference betweenthe mean hemoglobin values of the patients using this drug from September 2005 to February2006.